You are hereJune 19, 2017
What’s the Stem Cells Buzz this Week? – New TNBC Model, Aberrant Stem Cell Divisions, First-in-Man Stem Cell Trial, and Revascularization with UCBs!
A roundup of some of the new and exciting stories in the ever-changing world of stem cells, regenerative medicine, and beyond brought to you by the Stem Cells Portal
New TNBC Model Used to Delineate Cancer-Specific Signaling and Functions
Researchers from the lab of Henrik J. Ditzel (University of Southern Denmark) recently set out to discover how to target breast cancer stem cells (CSCs) by comparing two different sets of isogenic cells (one tumor initiating and one non-tumor initiating) derived from a triple-negative breast cancer cell line. Interestingly, this new STEM CELLS study indicates that cells that initiate tumors down-regulate their apoptotic pathway and display differential NF-κB and Wnt/β-catenin signaling. Can further analyses of these pathways provide druggable targets?
Aberrant Stem Cell Division found in Psoriasis
Taking their influence from cancer studies, researchers from the lab of Ruby Ghadially (UCSF, USA) have recently reported on their studies into the dysregulation of asymmetric stem cell divisions (ACDs) and symmetric cell divisions (SCDs) in the benign hyperproliferation of psoriasis. Their new STEM CELLS study suggests that IL7A, a target for inhibition for the treatment of psoriasis, increased asymmetric stem cell divisions associated with psoriasis. The authors note that this study highlights an important link between the immune system and skin proliferation.
First-in-Man Stem Cell Trial for Articular Cartilage Repair
Trophic support for regeneration by mesenchymal stem cells (MSCs) represents an important concept in many regenerative therapies. The lab of Daniel B.F. Saris (University Medical Center Utrecht, Netherlands) sought to harness this supporting role in a recent trial aimed at articular cartilage repair in a one-stage cell transplantation. The results of this trial, published in STEM CELLS, suggest that this strategy is safe and efficacious and supports a role for MSCs as a stimulator of our body’s inherent reparative/regenerative powers.
AD-Overexpressing UCB Cells Boost Revascularization
Motivate by the scarcity of therapeutically relevant cells, researchers from the lab of David A. Hess (Western University, Ontario, Canada) sought to ex vivo expand umbilical cord blood (UCB) progenitor cells with high aldehyde dehydrogenase (AD) activity for the treatment of ischemic tissue-related disease. Their recent STEM CELLS Translational Medicine study describes just how Putman et al. achieved 18-fold expansion under defined, serum-free conditions without diminishing vascular regenerative functions. Wow!
That’s a wrap for now! Please feel free to leave a comment and discuss the papers covered here on the Stem Cells Buzz. Happy reading!